Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Lyra Therapeutics, Inc. (LYRA)
|
Add to portfolio |
|
|
|
| Price: |
$4.35
| | Metrics |
| OS: |
49.5
|
M
| |
|
|
| Market cap: |
$216
|
M
| |
|
|
|
Net cash:
|
$54.4
|
M
| |
$1.10
|
per share
|
|
EV:
|
$161
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 0.3 | 0.0 | 0.0 | 5.0 |
| Revenue growth | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 8.7 |
| Gross profit | 0.3 | 0.0 | 0.0 | -3.7 |
| Gross margin | 100.0% | | | -75.0% |
| Research and development | 29.7 | 12.5 | 12.0 | |
| General and administrative | 14.2 | 9.7 | 4.5 | 3.5 |
| EBIT | -43.6 | -22.2 | -16.5 | -7.3 |
| EBIT margin | -15303.5% | | | -145.9% |
| Pre-tax income | -43.5 | -22.1 | -16.3 | -6.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -43.5 | -22.1 | -16.3 | -6.0 |
| Net margin | -15267.7% | | | -121.2% |
| |
| Diluted EPS | ($3.35) | ($2.58) | ($80.69) | ($36.30) |
| Shares outstanding (diluted) | 13.0 | 8.6 | 0.2 | 0.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|